In support of this hypothesis, we discover that treatment with abemaciclib leads to reduced tumor B7-H4 expression, enhanced T cell activation, and abolished tumor progression in mice bearing breast cancer and colorectal cancer. This evidence concerns the gene VTCN1 and colorectal cancer.